<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; drugs</title>
	<atom:link href="http://www.tapanray.in/tag/drugs/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>When Pills Betray Trust</title>
		<link>http://www.tapanray.in/when-pills-betray-trust/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=when-pills-betray-trust</link>
		<comments>http://www.tapanray.in/when-pills-betray-trust/#comments</comments>
		<pubDate>Sun, 02 Nov 2025 07:25:59 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[betray]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[lies]]></category>
		<category><![CDATA[life]]></category>
		<category><![CDATA[mindset]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[pharmaceuical]]></category>
		<category><![CDATA[pills]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[regulator]]></category>
		<category><![CDATA[Safety]]></category>
		<category><![CDATA[Spurious]]></category>
		<category><![CDATA[Standard]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[trust]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10993</guid>
		<description><![CDATA[Why India’s Drug Quality Crisis Demands a Mindset Reset? A Familiar Headline, a Fading Sense of Shock: It happened again. According to The Economic Times (October 24, 2025), 112 drug samples failed quality tests in September — one even found spurious. If that &#8230; <a href="http://www.tapanray.in/when-pills-betray-trust/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/when-pills-betray-trust/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>No Compromise: India Protects Patents Act in High-Stakes UK Trade Pact</title>
		<link>http://www.tapanray.in/no-compromise-india-protects-patents-act-in-high-stakes-uk-trade-pact/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=no-compromise-india-protects-patents-act-in-high-stakes-uk-trade-pact</link>
		<comments>http://www.tapanray.in/no-compromise-india-protects-patents-act-in-high-stakes-uk-trade-pact/#comments</comments>
		<pubDate>Wed, 30 Jul 2025 06:47:48 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2025]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[data exclusivity]]></category>
		<category><![CDATA[deal]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[ever greening]]></category>
		<category><![CDATA[FTA]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[no compromise]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Safeguards]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Trade]]></category>
		<category><![CDATA[UK]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10948</guid>
		<description><![CDATA[India, the &#8220;pharmacy of the world,&#8221; has long been a lifeline for millions, churning out affordable generic medicines that make healthcare accessible across the Global South. With over $25 billion generic drug industry exporting half its production, India’s commitment to &#8230; <a href="http://www.tapanray.in/no-compromise-india-protects-patents-act-in-high-stakes-uk-trade-pact/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/no-compromise-india-protects-patents-act-in-high-stakes-uk-trade-pact/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Access Denied, Ethics Demanded: India’s Pharma Detailing at a Turning Point</title>
		<link>http://www.tapanray.in/beyond-influence-a-new-era-of-ethical-medical-detailing-in-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=beyond-influence-a-new-era-of-ethical-medical-detailing-in-india</link>
		<comments>http://www.tapanray.in/beyond-influence-a-new-era-of-ethical-medical-detailing-in-india/#comments</comments>
		<pubDate>Fri, 13 Jun 2025 00:00:28 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[beyond]]></category>
		<category><![CDATA[branded]]></category>
		<category><![CDATA[detailing]]></category>
		<category><![CDATA[DGHS]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[era]]></category>
		<category><![CDATA[ethical]]></category>
		<category><![CDATA[generics]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[influence]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[limitations]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[patented]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[representation]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10913</guid>
		<description><![CDATA[June 11, 2025 — The Economic Times reports that a prominent pharmaceutical industry association has urged the Union Health Ministry to reconsider its directive that bars medical representatives (MRs) from physically meeting doctors in central government hospitals. The industry argues that the move &#8230; <a href="http://www.tapanray.in/beyond-influence-a-new-era-of-ethical-medical-detailing-in-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/beyond-influence-a-new-era-of-ethical-medical-detailing-in-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>The Unseen Terror: Fake Drugs Claim More Lives Than Terrorism in India</title>
		<link>http://www.tapanray.in/the-unseen-terror-fake-drugs-claim-more-lives-than-terrorism-in-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=the-unseen-terror-fake-drugs-claim-more-lives-than-terrorism-in-india</link>
		<comments>http://www.tapanray.in/the-unseen-terror-fake-drugs-claim-more-lives-than-terrorism-in-india/#comments</comments>
		<pubDate>Thu, 15 May 2025 07:43:47 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Counterfeit]]></category>
		<category><![CDATA[death]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Fake]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Spurious]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Terror]]></category>
		<category><![CDATA[terrorism]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10896</guid>
		<description><![CDATA[In May 2025, the Union Health Ministry acknowledged in a response to the Lok Sabha that over 7,500 drug samples failed quality tests across India in the previous year, with spurious drugs reported from nearly every major state. The admission, &#8230; <a href="http://www.tapanray.in/the-unseen-terror-fake-drugs-claim-more-lives-than-terrorism-in-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/the-unseen-terror-fake-drugs-claim-more-lives-than-terrorism-in-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Regulatory Failures Are Still Risking Patient Lives</title>
		<link>http://www.tapanray.in/regulatory-failures-are-still-risking-patient-lives/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=regulatory-failures-are-still-risking-patient-lives</link>
		<comments>http://www.tapanray.in/regulatory-failures-are-still-risking-patient-lives/#comments</comments>
		<pubDate>Sun, 06 Oct 2024 06:37:45 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[CDSCO]]></category>
		<category><![CDATA[Counterfeit]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[failures]]></category>
		<category><![CDATA[Fake]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[Leverage]]></category>
		<category><![CDATA[lives]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Report]]></category>
		<category><![CDATA[risking]]></category>
		<category><![CDATA[self-regulation]]></category>
		<category><![CDATA[standards]]></category>
		<category><![CDATA[substandard]]></category>
		<category><![CDATA[sustainabilitycompanies]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[TechnologyAwareness]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10880</guid>
		<description><![CDATA[India&#8217;s pharmaceutical industry faces renewed scrutiny as the Drug Controller General of India (DCGI) flagged numerous substandard drugs in September 2024. At the same time, an October 02, 2024, Business Standard report highlights an ongoing crackdown on such drugs by regulators. This article explores &#8230; <a href="http://www.tapanray.in/regulatory-failures-are-still-risking-patient-lives/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/regulatory-failures-are-still-risking-patient-lives/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Ticking Some Right Boxes Biosimilar Drugs’ Acceptance Gaining Steam in India</title>
		<link>http://www.tapanray.in/ticking-some-right-boxes-biosimilar-drugs-acceptance-gaining-steam-in-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=ticking-some-right-boxes-biosimilar-drugs-acceptance-gaining-steam-in-india</link>
		<comments>http://www.tapanray.in/ticking-some-right-boxes-biosimilar-drugs-acceptance-gaining-steam-in-india/#comments</comments>
		<pubDate>Sun, 24 Sep 2023 06:26:00 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[acceptance]]></category>
		<category><![CDATA[arbitrage]]></category>
		<category><![CDATA[Barriers]]></category>
		<category><![CDATA[Biologic]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[Boxes]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[doctors]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[initiatives]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[stakeholder]]></category>
		<category><![CDATA[support]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[ticking]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10828</guid>
		<description><![CDATA[Looking at a broader canvas, on September 19, 2023, a credible international report flashed a headline, ‘Biosimilars making inroads into Humira sales, but docs still cautious on switching: Spherix.’ This is based on a survey of U.S. healthcare specialists, including 80 dermatologists, &#8230; <a href="http://www.tapanray.in/ticking-some-right-boxes-biosimilar-drugs-acceptance-gaining-steam-in-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/ticking-some-right-boxes-biosimilar-drugs-acceptance-gaining-steam-in-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>India’s Drug Quality Concerns: Is Light At The End of The Tunnel In Sight Now?</title>
		<link>http://www.tapanray.in/indias-drug-quality-concerns-is-light-at-the-end-of-the-tunnel-in-sight-now/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=indias-drug-quality-concerns-is-light-at-the-end-of-the-tunnel-in-sight-now</link>
		<comments>http://www.tapanray.in/indias-drug-quality-concerns-is-light-at-the-end-of-the-tunnel-in-sight-now/#comments</comments>
		<pubDate>Mon, 07 Aug 2023 00:00:43 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[action]]></category>
		<category><![CDATA[big]]></category>
		<category><![CDATA[Code]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[end]]></category>
		<category><![CDATA[events]]></category>
		<category><![CDATA[GMP]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[light]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[QR]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[regulators]]></category>
		<category><![CDATA[Safety]]></category>
		<category><![CDATA[Saga]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[tunnel]]></category>
		<category><![CDATA[two=pronged]]></category>
		<category><![CDATA[WHO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10805</guid>
		<description><![CDATA[A brief chronology of some recent events on issues pertaining to patient-health-safety with drugs, as captured below, would possibly generate a mixed feeling for many. This includes a serious concern about, especially generic drug quality safety standards in India, on the one &#8230; <a href="http://www.tapanray.in/indias-drug-quality-concerns-is-light-at-the-end-of-the-tunnel-in-sight-now/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/indias-drug-quality-concerns-is-light-at-the-end-of-the-tunnel-in-sight-now/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>To Reduce Disease Burden India Launches A New Study On Access to Affordable Drugs</title>
		<link>http://www.tapanray.in/to-reduce-disease-burden-india-launches-a-new-study-on-access-to-affordable-drugs/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=to-reduce-disease-burden-india-launches-a-new-study-on-access-to-affordable-drugs</link>
		<comments>http://www.tapanray.in/to-reduce-disease-burden-india-launches-a-new-study-on-access-to-affordable-drugs/#comments</comments>
		<pubDate>Mon, 28 Mar 2022 00:00:33 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[AB-PMJAY]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[affordable]]></category>
		<category><![CDATA[Ayushman Bharat]]></category>
		<category><![CDATA[burden]]></category>
		<category><![CDATA[control]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[Coverage]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[Department]]></category>
		<category><![CDATA[disease]]></category>
		<category><![CDATA[DoP]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[health care]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[negotiation]]></category>
		<category><![CDATA[notification]]></category>
		<category><![CDATA[OOPE]]></category>
		<category><![CDATA[out of pocket]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[private]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[reduce]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10678</guid>
		<description><![CDATA[As India is struggling hard to come out of economic meltdown, and more – while navigating through the Covid-19 pandemic, the issue of reducing the National Disease Burden (NDP) with comprehensive measures resurfaces. According to a World Bank study, with ’17.5% &#8230; <a href="http://www.tapanray.in/to-reduce-disease-burden-india-launches-a-new-study-on-access-to-affordable-drugs/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/to-reduce-disease-burden-india-launches-a-new-study-on-access-to-affordable-drugs/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Create Novel Marketing Pathways As Covid Mutants Keep Emerging</title>
		<link>http://www.tapanray.in/create-novel-marketing-pathways-as-covid-mutants-keep-emerging/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=create-novel-marketing-pathways-as-covid-mutants-keep-emerging</link>
		<comments>http://www.tapanray.in/create-novel-marketing-pathways-as-covid-mutants-keep-emerging/#comments</comments>
		<pubDate>Mon, 10 Jan 2022 00:00:06 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[approvals]]></category>
		<category><![CDATA[branding]]></category>
		<category><![CDATA[brands]]></category>
		<category><![CDATA[Coronavirus]]></category>
		<category><![CDATA[corporate]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[emergency]]></category>
		<category><![CDATA[emerging]]></category>
		<category><![CDATA[EUA]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[molnupiravir]]></category>
		<category><![CDATA[mutants]]></category>
		<category><![CDATA[novel]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[pathways]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[use]]></category>
		<category><![CDATA[vaccines]]></category>
		<category><![CDATA[variants]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10634</guid>
		<description><![CDATA[The World’s battle against wave after wave unsettling onslaught of Coronavirus on human lives and livelihood continues, since December 2019. The first wave was triggered by the novel Covid-19 from Wuhan in China, the second by its deadly – Delta variant, &#8230; <a href="http://www.tapanray.in/create-novel-marketing-pathways-as-covid-mutants-keep-emerging/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/create-novel-marketing-pathways-as-covid-mutants-keep-emerging/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Focus On All 3 Areas of Innovation For Affordable Access To Innovative Drugs</title>
		<link>http://www.tapanray.in/focus-on-all-3-areas-of-innovation-for-affordable-access-to-innovative-drugs/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=focus-on-all-3-areas-of-innovation-for-affordable-access-to-innovative-drugs</link>
		<comments>http://www.tapanray.in/focus-on-all-3-areas-of-innovation-for-affordable-access-to-innovative-drugs/#comments</comments>
		<pubDate>Mon, 29 Nov 2021 00:00:53 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[ace]]></category>
		<category><![CDATA[affordable]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[changing]]></category>
		<category><![CDATA[Covid]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[differential]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[focus]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[innovative]]></category>
		<category><![CDATA[Issues]]></category>
		<category><![CDATA[Models]]></category>
		<category><![CDATA[outcomesbusiness]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[problem]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[solution]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[three areas]]></category>
		<category><![CDATA[tiered]]></category>
		<category><![CDATA[win-win]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10615</guid>
		<description><![CDATA[Medical treatment has made astonishing advances over the years. But the packaging and delivery of that treatment are often inefficient, ineffective, and consumer unfriendly. This was articulated in an article on innovation in healthcare, published in the Harvard Business Review, way &#8230; <a href="http://www.tapanray.in/focus-on-all-3-areas-of-innovation-for-affordable-access-to-innovative-drugs/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/focus-on-all-3-areas-of-innovation-for-affordable-access-to-innovative-drugs/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
